非小细胞肺癌EGFR基因突变治疗方案及医保政策回顾
Therapeutic Schedule of EGFR Mutation in Non-Small Cell Lung Cancer and Review of Health Insurance Policy
摘要: 表皮细胞生长因子受体(Epidermal Growth Factor Receptor, EGFR)基因突变是非小细胞肺癌患者(NSCLC)的主要突变之一，该突变的发现推动了小分子靶向药物研究的进展，促使NSCLC患者治疗方法多样化。临床通常采用外科手术切除治疗、放射治疗、化学治疗等传统治疗方案并配合使用分子靶向药物的联合治疗，增加了患者生存获益。本文综述EGFR基因突变的NSCLC患者靶向药物治疗以及部分地区医保政策，旨在为进一步治疗提供参考。
Abstract: The gene mutation of epidermal growth factor receptor (EGFR), which is one of the most vital mutations in patients with non-small cell lung cancer (NSCLC). The discovery of this mutation promotes the research progress of small molecule targeting drugs and the diversification of treatment methods. The therapy has increased the survival benefit of patients, especially those with invasivetumors, which is combinated with surgical resection, radiotherapy, chemotherapy and other traditional therapies combined with molecularly targeted drugs. This article reviews EGFR gene mutations in NSCLC patients targeted drug therapy and some regional health care policy, in order to provide a reference for further treatment.
文章引用：高婧, 王睿, 申越, 尹楠, 王文杰, 曹荣月. 非小细胞肺癌EGFR基因突变治疗方案及医保政策回顾[J]. 世界肿瘤研究, 2022, 12(3): 174-183. https://doi.org/10.12677/WJCR.2022.123024

参考文献

[1] 中国2022最新癌症统计数据详解[EB/OL]. https://wenku.baidu.com/view/d91b06d18aeb172ded630b1c59eef8c75fbf9519.htm, 2022-03-02.
[2] 郑彩云, 高晨杨, 施恩, 等. 非小细胞肺癌EGFR 20号外显子插入突变的药物研究进展[J]. 临床合理用药杂志, 2021, 14(10): 178-181.
[Google Scholar] [CrossRef] 
[3] Reck, M. and Rabe, K.F. (2017) Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 377, 849-861.
[Google Scholar] [CrossRef] 
[4] Dea, R., Den, S., Stevens, J., Wu, Y.L., et al. (2013) Mutation Incidence and Coincidence in Non-Small-Cell Lung Cancer: Meta-Analyses by Ethnicity and Histology (mutMap). Annals of Oncology, 24, 2371-2376.
[Google Scholar] [CrossRef] [PubMed]
[5] Cancer Genome Atlas Research Network (2014) Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature, 511, 543-550.
[Google Scholar] [CrossRef] [PubMed]
[6] Chen, Z., Fillmore, C.M., Hammerman, P.S., et al. (2014) Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases. Nature Reviews Cancer, 14, 535-546.
[Google Scholar] [CrossRef] [PubMed]
[7] Chen, L., Chen, R., Zhu, Z., et al. (2014) Predictive Factors Associated with Gefitinib Response in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Chinese Journal of Cancer Research, 26, 466-470.
[8] 官绍年, 陈迎珠, 卓明磊, 等. 非小细胞肺癌EGFR基因突变检测的临床应用进展[J]. 临床检验杂志, 2020, 38(2): 130-136.
[Google Scholar] [CrossRef] 
[9] 冯勇智. 表皮生长因子受体与肺癌[J]. 国外医学(内科学册), 2004, 31(1): 26-28+33.
[10] Yoshida, T., Zhang, G. and Haura, E.B. (2010) Targeting Epidermal Growth Factor Receptor: Central Signaling Kinase in Lung Cancer. Biochemical Pharmacology, 80, 613-623.
[Google Scholar] [CrossRef] [PubMed]
[11] 朱丽蒙, 韩雪莹, 马楠, 等. 肺癌表皮生长因子受体基因突变分型特征及临床意义研究[J]. 现代医药卫生, 2022, 38(6): 948-953.
[Google Scholar] [CrossRef] 
[12] 赵冉, 伍潇怡, 陈颖玮, 等. 二代测序技术检测650例非小细胞肺癌驱动基因突变[J]. 临床与实验病理学杂志, 2022, 38(2): 152-156.
[Google Scholar] [CrossRef] 
[13] Zhuo, M.L., Zheng, Q.W., Zhao, J., et al. (2017) Survival Difference between EGFR Del19 and L858R Mutant Advanced Non-Small Cell Lung Cancer Patients Receiving Gefitinib: A Propensity Score Matching Analysis. Chinese Journal of Cancer Research, 29, 553-560.
[Google Scholar] [CrossRef] [PubMed]
[14] NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
[15] Rosell, R., Moran, T., Queralt, C., et al. (2009) Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. The New England Journal of Medicine, 361, 958-967.
[Google Scholar] [CrossRef] 
[16] Lynch, T.J., Bell, D.W., Sordella, R., et al. (2004) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. The New England Journal of Medicine, 350, 2129-2139.
[Google Scholar] [CrossRef] 
[17] 申越, 王睿, 高婧, 等. 非小细胞肺癌小分子的靶向治疗研究进展[J]. 世界肿瘤研究, 2022, 12(2): 90-98.
[Google Scholar] [CrossRef] 
[18] 王旭, 高晓玲, 李建强. 贝伐珠单抗联合化疗治疗表皮生长因子受体无突变非小细胞肺癌的临床研究[J]. 中国药物与临床, 2018, 18(8): 1355-1357.
[19] Rikova, K., Guo, A., Zeng, Q., et al. (2007) Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell, 131, 1190-1203.
[Google Scholar] [CrossRef] [PubMed]
[20] Paez, J.G., Janne, P.A., Lee, J.C., et al. (2004) EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 304, 1497-1500.
[Google Scholar] [CrossRef] [PubMed]
[21] Pao, W., Miller, V., Zakowski, M., et al. (2004) EGF Receptor Gene Mutations Are Common in Lung Cancers from “Never Smokers” and Are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101, 13306-13311.
[Google Scholar] [CrossRef] [PubMed]
[22] 丛日楠, 谷芳, 王冰. 吉非替尼、厄洛替尼与埃克替尼治疗EGFR基因敏感突变晚期NSCLC患者的疗效观察[J]. 现代肿瘤医学, 2018, 26(2): 216-219.
[Google Scholar] [CrossRef] 
[23] Chen, X., Zhu, Q., Zhu, L., Pei, D., Liu, Y., Yin, Y., Schuler, M. and Shu, Y. (2013) Clinical Perspective of Afatinib in Non-Small Cell Lung Cancer. Lung Cancer, 81, 155-161.
[Google Scholar] [CrossRef] [PubMed]
[24] 徐芳. 吉非替尼与厄洛替尼在EGFR野生型晚期NSCLC三线及以上患者治疗中的效果比较[J]. 临床合理用药杂志, 2018, 11(19): 81-82.
[Google Scholar] [CrossRef] 
[25] 李萍, 王丽, 贾乐川. 第3代表皮生长因子受体抑制药——奥西替尼研究状况[J]. 中国临床药理学杂志, 2017, 33(14): 1371-1373.
[Google Scholar] [CrossRef] 
[26] 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志, 2019, 22(2): 57-81.
[Google Scholar] [CrossRef] [PubMed]
[27] 赵健, 杨达夫, 戴朝霞. 奥西替尼治疗32例晚期非小细胞肺癌的疗效观察[J]. 大连医科大学学报, 2019, 41(6): 511-516.
[28] Pan, Z., Wang, K., Wang, X., Jia, Z., et al. (2022) Cholesterol Promotes EGFR-TKIs Resistance in NSCLC by Inducing EGFR/Src/Erk/SP1 Signaling-Mediated ERRα Re-Expression. Molecular Cancer, 21, Article No. 77.
[Google Scholar] [CrossRef] [PubMed]
[29] 陆薇. EGFR-TKIs在非小细胞肺癌中的耐药机制及诊疗策略新进展[J]. 临床合理用药杂志, 2021, 14(10): 173-175.
[Google Scholar] [CrossRef] 
[30] Lynch, T.J., Kim, E.S., Eaby, B., et al. (2007) Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management. Oncologist, 12, 610-621.
[Google Scholar] [CrossRef] [PubMed]
[31] Melosky, B., Burkes, R., Rayson, D., et al. (2009) Management of Skin Rash during EGFR-Targeted Monoclonal Antibody Treatment for Gastrointestinal Malignancies: Canadian Recommendations. Current Oncology, 16, 16-26.
[Google Scholar] [CrossRef] [PubMed]
[32] Shah, N.T., Kris, M.G., Pao, W., et al. (2005) Practical Management of Patients with Non-Small-Cell Lung Cancer Treated with Gefitinib. Journal of Clinical Oncology, 23, 165-174.
[Google Scholar] [CrossRef] 
[33] Marushima, H., Kimura, H., Miyazawa, T., et al. (2020) Survival Outcomes of Adjuvant Chemotherapy with Modified Weekly Nab-Paclitaxel and Carboplatin for Completely Resected Nonsmall Cell Lung Cancer: FAST-Nab. Anti-Cancer Drugs, 31, 177-182.
[Google Scholar] [CrossRef] 
[34] 张家豪, 张亚杰, 李鹤成. 2020年V1版《NCCN非小细胞肺癌临床实践指南》更新解读[J]. 中国胸心血管外科临床杂志, 2020, 27(6): 614-618.
[Google Scholar] [CrossRef] 
[35] Pignon, J.P., Tribodet, H., Scagliotti, G.V., et al. (2008) Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26, 3552-3559.
[36] 黄纯碧, 李卫平, 许汝福, 等. 吉西他滨联合顺铂治疗晚期非小细胞肺癌的系统评价再评价[J]. 中国药房, 2022, 33(5): 622-627.
[Google Scholar] [CrossRef] 
[37] 黄学德, 黄欢彩, 林涛. 去甲长春花碱加顺铂治疗晚期非小细胞肺癌60例效果观察[J]. 海峡药学, 2018, 30(7): 214-215.
[38] 中国医师协会肿瘤医师分会, 中国抗癌协会肿瘤临床化疗专业委员会, 《中华医学杂志》编辑委员会. 中国重组人粒细胞集落刺激因子在肿瘤化疗中的临床应用专家共识(2015年版) [J]. 中华医学杂志, 2015, 95(37): 3001-3003.
[Google Scholar] [CrossRef] 
[39] 佚名. 天津: 将非小细胞肺癌特定药纳入医保[J]. 中国医疗保险, 2017(5): 71.
[40] 罗雪燕, 袁泉, 姚文兵. 埃克替尼用于治疗晚期非小细胞肺癌的预算影响分析[J]. 中国新药杂志, 2018, 27(9): 973-977.
[41] 陈风扬, 董作军, 王超军. EGFR-TKI和标准化疗治疗EGFR突变非小细胞肺癌药物经济学评价系统综述[J]. 上海医药, 2022, 43(5): 32-35+49.

为你推荐